Keytruda, a medication produced by Merck & Co. and used for the treatment of various forms of cancer, was first approved by the U.S. Food and Drug Administration (FDA) in 2014.
The FDA approved Keytruda (pembrolizumab) for the treatment of advanced melanoma in September 2014 [1]. Keytruda was the second PD-1/PD-L1 inhibitor approved by the FDA [1].
According to DrugPatentWatch.com, Keytruda was originally approved for "the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor" [2].
Sources:
[1] "FDA approves new treatment for advanced skin cancer." U.S. Food and Drug Administration. FDA, 04 Sept. 2014. Web. 12 May 2022. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-advanced-skin-cancer>.
[2] "Keytruda (pembrolizumab)." DrugPatentWatch.com. DrugPatentWatch, n.d. Web. 12 May 2022. <https://www.drugpatentwatch.com/drugs/keytruda>.